title: Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.
authors.forename: A
authors.initials: A
authors.lastname: Puissant
authors.forename: M
authors.initials: M
authors.lastname: Dufies
authors.forename: S
authors.initials: S
authors.lastname: Raynaud
authors.forename: J-P
authors.initials: JP
authors.lastname: Cassuto
authors.forename: P
authors.initials: P
authors.lastname: Auberger
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D002401:Cathepsin B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D008247:Lysosomes / Q000378:metabolism* / Q000473:pathology*; D009842:Oligopeptides / Q000494:pharmacology*; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*; D034741:RNA, Small Interfering / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D009842:Oligopeptides; D010879:Piperazines; D011743:Pyrimidines; D034741:RNA, Small Interfering; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C533912:CTSB protein, human; D002401:Cathepsin B